First FDA-Approved Recombinant von Willebrand Factor, Vonvendi, Now Available for von Willebrand Disease
The following is excerpted from a press release from Baxalta, now a part of Shire. Read the press release in it’s entirety here.Shire has announced that Vonvendi [von Willebrand factor (Recombinant)], indicated for the on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease, is now available […]
Biogen Names New Spin Off, Bioverativ; Aiming for Early 2017 Launch
The following is an excerpt from FierceBiotech.com To read the article in full, click here.Biogen previously announced its plan to spin out its blood disorder products and candidates into a separate publicly traded company. The new company will be known as Bioverativ and is slated to launch in early 2017 and trade on the Nasdaq market. It […]
English 
Español de Puerto Rico